EyePoint Pharmaceuticals

124 articles about EyePoint Pharmaceuticals

• EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties

  5/18/2023

  EyePoint Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the sale of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences, Inc. (“Alimera”).

• Alimera Acquires U.S. Commercial Rights to YUTIQ®

  5/18/2023

  Alimera Sciences, Inc. today announced its acquisition of additional commercialization rights for YUTIQ (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals, Inc. (EyePoint).

• EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments

  5/3/2023

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter ended March 31, 2023 and highlighted recent corporate developments.

• EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023

  4/26/2023

  EyePoint Pharmaceuticals, Inc. today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 3, 2023 to report its first quarter 2023 financial results and highlight recent corporate developments.

• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 17, 2023

  4/17/2023

  EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD

  3/27/2023

  EyePoint Pharmaceuticals, Inc. today announced it has completed enrollment in the Phase 2 "Durasert® and Vorolanib in Ophthalmology 2" (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance treatment for wet age-related macular degeneration (wet AMD).

• EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

  3/20/2023

  EyePoint Pharmaceuticals, Inc. today announced multiple scientific presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held April 23 – 27 in New Orleans, Louisiana.

• EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

  3/2/2023

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the fourth quarter and year ended December 31, 2022 and highlighted recent corporate developments.

• EyePoint Pharmaceuticals Announces Participation at Upcoming March 2023 Investor Conferences

  2/27/2023

  EyePoint Pharmaceuticals, Inc. announced that EyePoint Pharmaceuticals will present at the following upcoming conferences.

• EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

  2/27/2023

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a research collaboration.

• EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023

  2/23/2023

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full-year 2022 financial results and highlight recent corporate developments.

• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 16, 2023

  2/16/2023

  EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

  1/23/2023

  EyePoint Pharmaceuticals, Inc. today announced that it has entered into a lease agreement to to design and construct a 40,000-square-foot manufacturing facility in Northbridge, Massachusetts to support the global manufacturing of programs, including EYP-1901 and YUTIQ.

• EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

  1/5/2023

  EyePoint Pharmaceuticals, Inc. announced a business update and key 2023 clinical timelines for its lead product candidate, EYP-1901.

• EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

  1/4/2023

  EyePoint Pharmaceuticals, Inc. today announced that Jay S. Duker, M.D., who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President.

• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - December 16, 2022

  12/16/2022

  EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - November 16, 2022

  11/16/2022

  EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• EyePoint Pharmaceuticals Announces Participation at Upcoming November 2022 Investor Conferences

  11/7/2022

  EyePoint Pharmaceuticals, Inc. announced that EyePoint Pharmaceuticals will present at the following upcoming conferences.

• EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

  11/2/2022

  EyePoint Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments.

• EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

  10/26/2022

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments.